This is a phase I, open-label, dose-escalation, multi-site trial including subjects with peanut allergy confirmed by screening double-blind, placebo-controlled food challenge. The trial is conducted in 2 parts; part 1 will determine the entry dose of the up-dosing regimen (UDR) in adults and adolescents and part 2 will characterize the tolerability of the up-dosing regimen in adults, adolescents and children.~Peanut SLIT tablets administered as 9 doses covering a 4000-fold increase in dose will be used in the study.~In part 1, subjects will receive a peanut SLIT-tablet with one of five increasing doses once daily for 2 weeks.~In part 2, subjects will receive a series of increasing doses of the peanut SLIT-tablet, where each dose is taken once daily for 2 weeks. The entry dose for the up dosing regimen will be determined from part 1.~The trial will consist of up to 10 cohorts (part 1 is cohort 1-5; part 2 is cohort 6-10).
This clinical research study investigates the safety and tolerability of a peanut SLIT-tablet.